Grigg et al.
mg, 1.0 mmol) in DMF (5 mL) at 60 °C for 3 h. The crude product
was purified by flash chromatography (eluting with EtOAc) to give
18e (172 mg, 77%) as colorless prisms: mp 215-217 °C (from
DCM-hexane); Rf 0.42 (EtOAc); δH (500 MHz, CDCl3, 60 °C)
8.15 (1H, d, J 7.6), 7.83 (2H, br m), 7.50 (1H, td, J 7.6 and 1.2),
7.43 (1H, td, J 7.6 and 1.2), 7.38 (3H, m), 7.17 (1H, t, J 7.3), 6.40
(1H, br s), 3.89 (4H, br m), 3.79 (1H, br m), 3.61 (1H, br m), 3.18
(2H, br m), 2.99 (1H, br m), 2.59 (1H, dd, J 16.3 and 4.6), 2.02
(3H, br s), 1.48 (2H, br m), 1.31 (2H, br m); δC (75 MHz, CDCl3)
174.8 (C),167.0 (C), 163.0 (C), 142.9 (C), 142.0 (C), 133.7 (CH),
129.8 (CH), 129.6 (CH), 128.9 (CH), 127.5 (C), 125.9 (CH), 120.8
(CH), 119.5 (CH), 106.9 (C), 64.8 (CH2), 51.8 (CH), 43.6 (CH2),
Experimental Section
General Procedure (A) for the Synthesis of Isoindolones. The
reagents were stirred in toluene (presaturated with carbon monoxide)
in a round-bottomed flask with palladium acetate added last. A
balloon containing carbon monoxide (CO) was used to flush the
system of air and maintain an atmosphere of CO while the stirred
reaction mixture was heated.
General Procedure (B) for the Synthesis of Phthalazones. A
carousel tube was loaded with the reagents and the solvent added
last. A balloon containing carbon monoxide (CO) was used to flush
the system of air via a PTFE cap fitted with septum and to maintain
an atmosphere of CO while the stirred reaction mixture was heated.
General Procedure (C) for the Synthesis of Phthalazones. A
carousel tube was loaded with the hydrazine salt, cesium carbonate,
water, and DMF and allowed to stir at 25 °C for 5 min before the
remainder of the reagents were added. A balloon containing carbon
monoxide (CO) was used to flush the system of air via a PTFE
cap fitted with septum and to maintain an atmosphere of CO while
the reaction was heated.
Methyl {2-[(2,5-difluorophenyl)amino]-3-oxo-2,3-dihydro-1H-
isoindol-1-yl}acetate (15a). Prepared by general procedure A from
methyl 3-(2-iodophenyl)acrylate 13a (144 mg, 0.5 mmol), 2,5-
difluorophenylhydrazine 14a (86 mg, 0.6 mmol), palladium acetate
(6 mg, 0.025 mmol), triphenylphosphine (13 mg, 0.05 mmol), and
cesium carbonate (324 mg, 1.0 mmol) in toluene (10 mL) at 90 °C
over 3 h. The crude product was purified by flash chromatography
(eluting with 3:7 v/v EtOAc-hexane) to give 15a (100 mg, 60%)
as a pale brown gum: Rf 0.25 (3:7 v/v EtOAc-hexane); δH (300
MHz, CDCl3) 7.91 (1H, d, J 7.7), 7.66 (1H, t, J 7.7), 7.65 (1H, d,
J 7.7), 7.54 (1H, t, J 7.7), 7.00 (1H, ddd, JHF 10.7, JHH 8.7, and
4JHF 5.1), 6.56-6.48 (1H, m), 6.46 (1H, br s), 6.44-6.38 (1H, m),
5.19 (1H, t, J 6.2), 3.65 (3H, s), 3.02 (1H, dd, J 15.9 and 6.2), 2.82
(1H, dd, J 15.9 and 6.2); δC (75 MHz, CDCl3) 171.0 (C), 167.4
(C), 162.9 (CF, d, J 235), 147.6 (CF, d, J 235), 143.4 (C), 136.5
(C, d, J 23), 133.3 (CH), 130.1 (C), 129.5 (CH), 124.8 (CH), 123.4
(CH), 116.4 (CH, dd, J 21 and 10), 107.3 (CH, dd, J 24 and 8),
101.9 (CH, d, J 28), 58.4 (CH), 52.5 (CH3), 37.3 (CH2); νmax/cm-1
(film) 3278, 2955, 1716 (CdO), 1633 (CdO), 1515, 1471; m/z
(ES+) 333 (100, MH+); HRMS (ES+) found MH+ 333.1046,
C17H14F2N2O3 requires MH+ 333.1045.
40.4 (CH2), 36.2 (CH2), 35.4 (CH2), 35.1 (CH2), 22.3 (CH3); νmax
/
cm-1 (film) 3062, 2961, 2930, 2884, 1696 (CdO), 1674 (CdO),
1642 (CdO), 1596, 1489, 1456; m/z (ES+) 921 (100, M2Na+),
472 (36, MNa+), 450 (14, MH+); HRMS (ES+) found MH+
450.2016, C25H27N3O5 requires MH+ 450.2023.
Methyl (2,3-Diethyl-4-oxo-1,2,3,4-tetrahydrophthalazin-1-yl)ac-
etate (18f). Prepared by general procedure C from methyl 3-(2-
iodophenyl)acrylate 13a (144 mg, 0.5 mmol), 1,2-diethylhydrazine
dihydrochloride 16b (104 mg, 0.65 mmol) in water (0.5 mL),
palladacycle 17 (19 mg, 0.025 mmol), and cesium carbonate (326
mg, 1.0 mmol) in DMF (5 mL) at 70 °C over 3 h. The crude product
was purified by flash chromatography (eluting with 1:9 v/v
EtOAc-DCM) to give 18f (76 mg, 55%) as a colorless gum: Rf
0.56 (1:9 v/v EtOAc-DCM); δH (500 MHz, CDCl3) 8.03 (1H, dd,
J 7.7 and 1.1), 7.48 (1H, td, J 7.7 and 1.1), 7.39 (1H, td, J 7.7 and
1.1), 7.20 (1H, d, J 7.7), 4.52 (1H, dd, J 9.0 and 5.6), 4.15 (1H,
dq, J 13.7 and 7.3), 3.71 (3H, s), 3.13 (1H, dq, J 13.7 and 7.3),
2.90-2.80 (2H, m), 2.70 (1H, dq, J 12.4 and 7.3), 2.53 (1H, dd, J
15.8 and 5.6), 1.26 (3H, t, J 7.3), 1.05 (3H, t, J 7.3); δC (75 MHz,
CDCl3) 171.6 (C), 162.6 (C), 137.8 (C), 132.8 (CH), 128.5 (CH),
127.9 (CH), 127.3 (C), 126.6 (CH), 56.1 (CH), 52.2 (CH3), 49.5
(CH2), 42.3 (CH2), 40.2 (CH2), 13.3 (CH3), 12.8 (CH3); νmax/cm-1
(film) 2975, 2951, 2853, 1741 (CdO), 1650 (CdO), 1605; m/z
(ES+) 277 (51, MH+), 299 (100, MNa+), 575 (70, M2Na+); HRMS
(ES+) found MNa+ 299.1375, C15H20N2O3 requires MNa+ 299.1366.
3
3
Acknowledgment. We thank Leeds University for technical
support and for the award of a Mary and Alice Smith
Scholarship (to S.M.) and GlaxoSmithKline for funding.
3-Acetyl-4-[2-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-2-oxoethyl]-
2-phenyl-3,4-dihydro-2H-phthalazin-1-one (18e). Prepared by
general procedure B from a stirred mixture of 8-[(2E)-3-(2-iodo-
phenyl)prop-2-enoyl]-1,4-dioxa-8-azaspiro[4.5]decane 13e (200 mg,
0.5 mmol), 1-acetyl-2-phenylhydrazine 16a (105 mg, 0.7 mmol),
palladacycle 17 (19 mg, 0.025 mmol), and cesium carbonate (326
Supporting Information Available: 1H and 13C NMR spec-
tra and CIF files of the X-ray structures. This material is
JO800822P
8356 J. Org. Chem. Vol. 73, No. 21, 2008